US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YD Bio Ltd

8.43

+0.36504.53%

Volume:11.03K

Turnover:92.29K

Market Cap:594.14M

PE:-8.53

High:8.50

Open:8.21

Low:8.21

Close:8.06

52wk High:31.00

52wk Low:5.30

Shares:70.52M

Float Shares:13.27M

Volume Ratio:0.60

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9880

EPS(LYR):-1.2901

ROE:-42.69%

ROA:-25.43%

PB:90.15

PE(LYR):-6.53

Loading ...

Overview Company News Filings

BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co

BUZZ-YD Bio rises as it signs U.S. regulatory partnership

YD Bio USA Partners With YC Biotech to Build Taiwan-U.S. Dual-Core FDA Regulatory Platform

Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

THOMSON REUTERS

Yd Bio Ltd: Yd Bio USA Will Serve as Yc Biotech's Exclusive U.S. Agent and Formal Liaison With FDA

THOMSON REUTERS

Yd Bio Ltd - Partnership Covers FDA-Related Projects Including Ind, Nda, Bla Submissions

THOMSON REUTERS

YD Bio Limited to Acquire Safe Save Medical Cell Sciences & Technology

Yd Bio Limited Enters Into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

THOMSON REUTERS

Yd Bio Ltd - to Buy Ky Company for US$26.87 Million

THOMSON REUTERS

YD Bio Limited Appoints Dr. Chang and Dr. Lu to Key Board Roles

YD Bio Limited Appoints Dr. Kochi Chang and Dr. Shao-Da Lu to Board

BRIEF-Yd Bio Enters Into MoU To Merge With Eg Biomed

YD Bio Limited Signs MOU to Merge with EG BioMed

Yd Bio Enters Into Mou to Merge With Eg Biomed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

THOMSON REUTERS

BRIEF-Yd Bio Ltd - Plans To Evaluate Up To Three Acquisitions In 2026

Yd Bio Ltd - Plans to Evaluate up to Three Acquisitions in 2026

THOMSON REUTERS

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Plans California Operations Center to Boost U.S. Cancer Diagnostics

YD Bio Showcases Cancer Detection Advances at 9th Healthcare Expo Taiwan

Yd Bio Limited Expands Okaidx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/YDES/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"YDES","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YDES\",,,,,undefined,":{"symbol":"YDES","market":"US","secType":"STK","nameCN":"YD Bio Ltd","latestPrice":8.425,"timestamp":1772053200000,"preClose":8.06,"halted":0,"volume":11034,"delay":0,"changeRate":0.04528535980148886,"floatShares":13265400,"shares":70521359,"eps":-0.988,"marketStatus":"Pre-Mkt","change":0.365,"latestTime":"02-26 06:00:44 EST","open":8.21,"high":8.5,"low":8.21,"amount":92292.6612,"amplitude":0.03598,"askPrice":13.25,"askSize":200,"bidPrice":7.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.988,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"listingDate":1756440000000,"exchange":"NASDAQ","adjPreClose":8.425,"postHourTrading":{"tag":"盘后","latestPrice":8.425,"preClose":8.425,"latestTime":"16:10 EST","volume":1,"amount":8.425,"timestamp":1772053804802,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5975517220474862},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YDES\",,,,,undefined,":{"symbol":"YDES","floatShares":13265400,"roa":"-25.43%","roe":"-42.69%","lyrEps":-1.290101,"volumeRatio":0.5975517220474862,"shares":70521359,"dividePrice":0,"high":8.5,"amplitude":0.03598,"preClose":8.06,"low":8.21,"week52Low":5.3,"pbRate":"90.15","psRate":"1164.16","week52High":31,"institutionHeld":0,"latestPrice":8.425,"committee":-0.333333,"eps":-0.988,"divideRate":0,"volume":11034,"delay":0,"ttmEps":-0.988,"open":8.21,"prevYearClose":12.19,"prevWeekClose":8.022,"prevMonthClose":11.87,"prevQuarterClose":12.19,"fiveDayClose":8.522,"twentyDayClose":12.16,"sixtyDayClose":10.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YDES\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-19","symbol":"YDES","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755576000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YDES\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YDES\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/YDES\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"YDES","date":"2026-02-25","current":-8.527328,"percent":0.991071,"low":-1151.273969,"twenty":-870.305332,"median":-610.259893,"eighty":-537.82578,"high":-399.63305,"avg":-662.167142,"sd":177.060095,"marketCap":566777781},"quantilePoints":[{"date":"2025-09-19","current":-961.968859,"twenty":-999.829881,"median":-916.635267,"eighty":-851.374822,"marketCap":1357875801},{"date":"2025-09-26","current":-709.645075,"twenty":-998.136098,"median":-925.353266,"eighty":-851.374822,"marketCap":1001705892},{"date":"2025-10-03","current":-960.225259,"twenty":-973.028263,"median":-916.635267,"eighty":-851.374822,"marketCap":1355414607},{"date":"2025-10-10","current":-932.078579,"twenty":-963.563007,"median":-911.653554,"eighty":-851.474456,"marketCap":1315683907},{"date":"2025-10-17","current":-939.800234,"twenty":-960.573979,"median":-919.624296,"eighty":-852.27153,"marketCap":1326583479},{"date":"2025-10-24","current":-877.279731,"twenty":-963.563007,"median":-920.745181,"eighty":-864.327276,"marketCap":1238332100},{"date":"2025-10-31","current":-553.468359,"twenty":-960.573979,"median":-906.67184,"eighty":-851.474456,"marketCap":781253244},{"date":"2025-11-07","current":-468.779231,"twenty":-944.084508,"median":-894.715728,"eighty":-771.61759,"marketCap":661709543},{"date":"2025-11-14","current":-504.149397,"twenty":-939.850051,"median":-872.298018,"eighty":-562.236175,"marketCap":711636618},{"date":"2025-11-21","current":-416.471241,"twenty":-935.217058,"median":-854.36385,"eighty":-532.644798,"marketCap":587873728},{"date":"2025-11-28","current":-574.391556,"twenty":-932.875653,"median":-852.122079,"eighty":-497.174998,"marketCap":810787570},{"date":"2025-12-05","current":-636.164802,"twenty":-928.790648,"median":-849.382136,"eighty":-516.703315,"marketCap":897984152},{"date":"2025-12-12","current":-626.201375,"twenty":-924.506374,"median":-777.645464,"eighty":-530.751747,"marketCap":883920187},{"date":"2025-12-19","current":-564.677215,"twenty":-922.364238,"median":-692.707249,"eighty":-539.021391,"marketCap":797075205},{"date":"2025-12-26","current":-621.717833,"twenty":-920.969359,"median":-645.630058,"eighty":-546.593595,"marketCap":877591403},{"date":"2026-01-02","current":-607.270864,"twenty":-919.02649,"median":-636.164802,"eighty":-555.660313,"marketCap":857198654},{"date":"2026-01-09","current":-614.245263,"twenty":-914.642582,"median":-629.688575,"eighty":-564.477946,"marketCap":867043429},{"date":"2026-01-16","current":-568.911671,"twenty":-905.326777,"median":-626.699546,"eighty":-565.524106,"marketCap":803052390},{"date":"2026-01-23","current":-612.750749,"twenty":-899.946527,"median":-622.714176,"eighty":-564.677215,"marketCap":864933835},{"date":"2026-01-30","current":-549.482989,"twenty":-896.708414,"median":-621.717833,"eighty":-564.677215,"marketCap":775627658},{"date":"2026-02-06","current":-536.032363,"twenty":-892.723043,"median":-616.73612,"eighty":-563.929958,"marketCap":756641306},{"date":"2026-02-13","current":-488.706085,"twenty":-877.279731,"median":-614.494349,"eighty":-554.464703,"marketCap":689837473},{"date":"2026-02-20","current":-438.39078,"twenty":-873.294361,"median":-611.928766,"eighty":-547.988475,"marketCap":618814451},{"date":"2026-02-25","current":-401.526101,"twenty":-870.305332,"median":-610.259893,"eighty":-537.82578,"marketCap":566777781}],"updateTime":1772103644948},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YDES\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614608700","title":"BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614608700?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:33","pubTimestamp":1772026434,"startTime":"0","endTime":"0","summary":"BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech CoFeb 25 (Reuters) - YD Bio Ltd YDES.O:YD BIO LIMITED ANNOUNCES STRATEGIC PARTNERSHIP WITH YC BIOTECH CO., LTD. TO ESTABLISH A TAIW","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA9SXQSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2614566087","title":"BUZZ-YD Bio rises as it signs U.S. regulatory partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2614566087","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614566087?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:18","pubTimestamp":1772025500,"startTime":"0","endTime":"0","summary":"BUZZ-YD Bio rises as it signs U.S. regulatory partnership** Shares of Biotechnology company YD Bio YDES.O rise 3.97% to $8.38 premarket** Co says it signed a U.S. regulatory partnership with YC Biotech, an Asiabased technical and regulatory support firm, to help drug and device makers navigate FDA approvals** Co says it will act as YC Biotech's exclusive U.S. representative, handling FDA communication and guiding clients from early meetings to final submissions** YDES says the deal marks a shift toward a broader platform model that may expand into Europe** Co says partnership expected to boost service offerings and support client growth** Shares up ~8% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL18J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2614427082","title":"YD Bio USA Partners With YC Biotech to Build Taiwan-U.S. Dual-Core FDA Regulatory Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2614427082","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614427082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:02","pubTimestamp":1772024532,"startTime":"0","endTime":"0","summary":"YD Bio Limited said its subsidiary YD Bio USA, Inc. has signed a master strategic alliance agreement with YC Biotech Co., Ltd. to build a Taiwan-U.S. “dual-core” regulatory platform. Under the deal, YD Bio USA will act as YC Biotech’s exclusive U.S. Agent and liaison to the FDA, supporting regulatory strategy, communications and inspection readiness, while YC Biotech will lead client acquisition and execution in Asia and help prepare IND, NDA, BLA and other FDA-related submissions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL4MHhf4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","BK4585","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","YDES","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","BK4112","SG9999014021.USD","NDAQ","BK4139"],"gpt_icon":0},{"id":"2614082945","title":"Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082945","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082945?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:00","pubTimestamp":1772024401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA9SXQSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2614082499","title":"Yd Bio Ltd: Yd Bio USA Will Serve as Yc Biotech's Exclusive U.S. Agent and Formal Liaison With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082499?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:00","pubTimestamp":1772024401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA9SXQSJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2614082121","title":"Yd Bio Ltd - Partnership Covers FDA-Related Projects Including Ind, Nda, Bla Submissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082121?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:00","pubTimestamp":1772024401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA9SXQSJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2607804390","title":"YD Bio Limited to Acquire Safe Save Medical Cell Sciences & Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804390","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607804390?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:30","pubTimestamp":1769693430,"startTime":"0","endTime":"0","summary":"YD Bio Limited has entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. , a Taiwan-based dendritic cell immunotherapy platform. The agreement involves a combination of newly issued YD Bio Ltd shares and cash, with SSMC's founder and major shareholders set to receive shares through a swap, while other shareholders can choose between cash or shares. Newly issued shares will be subject to lock-up periods of six months for general shareholders and one year for specific shareholders. The transaction aims to accelerate YD Bio Ltd’s expansion into advanced cell and gene therapies, complementing its recent integration of DNA-methylation-driven AI platforms for cancer diagnostics. The acquisition is expected to enhance research and development capabilities and broaden the company’s portfolio in innovative cancer treatment solutions. Completion is subject to due diligence and other customary conditions, with closing targeted shortly after Marc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL3K4XQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","YDES","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2607428080","title":"Yd Bio Limited Enters Into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2607428080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607428080?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:30","pubTimestamp":1769693401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA3QTBJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2607080444","title":"Yd Bio Ltd - to Buy Ky Company for US$26.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607080444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607080444?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:30","pubTimestamp":1769693401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA3QTBJL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2605299105","title":"YD Bio Limited Appoints Dr. Chang and Dr. Lu to Key Board Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2605299105","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605299105?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:03","pubTimestamp":1768993421,"startTime":"0","endTime":"0","summary":"YD Bio Limited has appointed Dr. Chang as Chairman of the Compensation Committee and as a member of the Audit Committee and Nominating and Corporate Governance Committee. Dr. Lu has been named Chairman of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee and Compensation Committee. These appointments are effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL3ZMD72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2603674459","title":"YD Bio Limited Appoints Dr. Kochi Chang and Dr. Shao-Da Lu to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2603674459","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603674459?lang=en_us&edition=fundamental","pubTime":"2026-01-16 19:02","pubTimestamp":1768561376,"startTime":"0","endTime":"0","summary":"YD Bio Limited announced changes to its Board of Directors effective December 30, 2025. Four directors—Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs, and Janet Hall—have been removed. Dr. Kochi Chang and Dr. Shao-Da Lu have been appointed as new board members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLNq8gN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2601431815","title":"BRIEF-Yd Bio Enters Into MoU To Merge With Eg Biomed","url":"https://stock-news.laohu8.com/highlight/detail?id=2601431815","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601431815?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:57","pubTimestamp":1767711440,"startTime":"0","endTime":"0","summary":"BRIEF-Yd Bio Enters Into MoU To Merge With Eg BiomedJan 6 (Reuters) - YD Bio Ltd YDES.O:YD BIO ENTERS INTO MOU TO MERGE WITH EG BIOMED, ADVANCING DNA METHYLATION–DRIVEN AI PLATFORMS FOR CANCER DIAGNOS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3LQMJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2601818997","title":"YD Bio Limited Signs MOU to Merge with EG BioMed","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818997","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818997?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:00","pubTimestamp":1767708033,"startTime":"0","endTime":"0","summary":"YD Bio Limited has entered into a Memorandum of Understanding to merge with EG BioMed, a biotechnology company specializing in DNA methylation-based cancer diagnostics and AI-driven biomarker analytics. The proposed combination aims to create an integrated oncology platform focused on early cancer detection, clinical data generation, and AI-enabled drug discovery. If completed, the merger could accelerate the transition toward a platform-based biotech organization anchored in clinically validated molecular data. EG BioMed is expected to contribute advanced DNA methylation diagnostics, AI biomarker algorithms, and clinical laboratory infrastructure, supporting both diagnostics commercialization and therapeutic innovation. The transaction is anticipated to close in 2026, pending the finalization of definitive agreements and other customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLbnWNGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","YDES","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2601818602","title":"Yd Bio Enters Into Mou to Merge With Eg Biomed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818602?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:00","pubTimestamp":1767708004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3LQMJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2601988227","title":"BRIEF-Yd Bio Ltd - Plans To Evaluate Up To Three Acquisitions In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988227?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:15","pubTimestamp":1767622515,"startTime":"0","endTime":"0","summary":"BRIEF-Yd Bio Ltd - Plans To Evaluate Up To Three Acquisitions In 2026YD Bio Ltd YDES.O:YD BIO LTD - PLANS TO EVALUATE UP TO THREE ACQUISITIONS IN 2026Source text: ID:nGNX4xQnclFurther company coverage: YDES.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"gpt_icon":0},{"id":"2601882612","title":"Yd Bio Ltd - Plans to Evaluate up to Three Acquisitions in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882612?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:09","pubTimestamp":1767622174,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YDES"],"gpt_icon":0},{"id":"2601825458","title":"YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap","url":"https://stock-news.laohu8.com/highlight/detail?id=2601825458","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601825458?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:00","pubTimestamp":1767621600,"startTime":"0","endTime":"0","summary":"Taipei, Taiwan, Jan.  05, 2026  (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212819/0/en/YD-Bio-Limited-Announces-Major-Milestones-and-Unveils-Robust-2026-Clinical-and-Commercial-Roadmap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2355687059.USD","LU0149725797.USD","BK4585","BK4543","LU1880398554.USD","LU0081259029.USD","LU1988902786.USD","IE00BFXG1179.USD","LU1303367103.USD","LU2237443465.HKD","LU0823434740.USD","LU0979878070.USD","IE00BHPRN162.USD","LU0823434583.USD","LU1803068979.SGD","LU2237443895.HKD","BK4529","LU0882574139.USD","LU2360106780.USD","LU0082616367.USD","LU1852331112.SGD","LU0109392836.USD","BK4588","LU0823421333.USD","LU1989764664.SGD","IE00BMPRXR70.SGD","LU2237443978.SGD","IE0009356076.USD","LU1951198990.SGD","BK4575","LU2458330169.SGD","BK4534","LU0127658192.USD","LU0390134368.USD","LU0274383776.USD","LU2237443622.USD","BK4006","LU1951200564.SGD","IE00BMPRXN33.USD","LU1880398471.USD","BK4141","BK4554","LU1861558580.USD","LU1064131342.USD","LU1861559042.SGD","LU0198837287.USD","IE00BZ1G4Q59.USD","BK4614","LU2458330243.SGD","LU1363072403.SGD","LU1316542783.SGD","LU0267386448.USD","IE00BKVL7J92.USD","BK4532","LU0889565833.HKD","BK4612","LU2746668974.SGD","BK4196","LU2054465674.USD","BK4605","LU0170899867.USD","LU2264538146.SGD","LU0971096721.USD","LU1242518931.SGD","LU2746668461.USD","LU0823421416.USD","LU1242518857.USD","LU2089985449.USD","YDES","BK4512","IE00B1BXHZ80.USD","LU2250418816.HKD","LU0719512351.SGD","IE0004445239.USD","LU1923623000.USD","LU0642271901.SGD","LU0056508442.USD","LU2237443382.USD","BK4573","LU2931357623.SGD","BK4566","LU2237443549.SGD","IE00B5949003.HKD","LU2098885051.SGD"],"gpt_icon":0},{"id":"2591808779","title":"YD Bio Limited Plans California Operations Center to Boost U.S. Cancer Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2591808779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591808779?lang=en_us&edition=fundamental","pubTime":"2025-12-16 22:01","pubTimestamp":1765893677,"startTime":"0","endTime":"0","summary":"YD Bio Limited, a biotechnology company specializing in DNA methylation-based cancer detection and ophthalmologic innovations, has announced plans to expand its U.S. presence with new facilities and an operations center in California. This initiative aims to accelerate clinical development, regulatory engagement, and commercial access for the company's next-generation diagnostics and exosome-based therapeutics. The California center will also align with the recent investment by YD Bio's partner, 3D Global Biotech Inc., which is building a GMP cell therapy manufacturing plant in the U.S. YD Bio will recruit U.S.-based talent and activate the new site in phases, supporting global R&D, regulatory, and commercialization activities. The specific location in California is still under evaluation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL7wFGDl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","YDES","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2590443253","title":"YD Bio Showcases Cancer Detection Advances at 9th Healthcare Expo Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590443253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590443253?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:00","pubTimestamp":1765288851,"startTime":"0","endTime":"0","summary":"YD Bio Limited showcased its latest advancements in DNA methylation-based cancer detection and ophthalmologic innovations at the 9th Healthcare Expo Taiwan, held from December 4-7, 2025, at TaipeiNEX 1. Presenting at Booth No. 4F, M1004, the company highlighted its early cancer detection technologies, precision diagnostics, and stem cell therapy platforms. YD Bio engaged with over 1,500 visitors and conducted 541 on-site surveys, connecting with key industry stakeholders and international distributors. The event marked a significant step in YD Bio's global commercialization strategy, with strong interest from partners in China, Hong Kong, Indonesia, and Dubai to expand the reach of its OkaiDx and other diagnostic products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL5lpTSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","LU2210150020.SGD","BK4139","YDES","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2588056242","title":"Yd Bio Limited Expands Okaidx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056242?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA6S1XMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YDES"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}